NCT06807281招募中3 期
A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Pfizer
- 入组人数
- 500
- 试验地点
- 43
- 主要终点
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
研究概览
简要总结
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
详细描述
Phase 3, open-label study to assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children ≥2 years of age with moderate-to-severe atopic dermatitis (AD). This study will enroll participants in two cohorts: an extension cohort of participants who previously completed prior abrocitinib studies, and a de novo cohort of participants (6 to <12 years of age) who have not participated in previous abrocitinib studies. Study duration will be up to 2 years (or commercial availability, whichever occurs earlier). The study will enroll a maximum of approximately 500 participants with moderate-to-severe Atopic Dermatitis from study sites globally (extension cohort will enroll up to 320 participants; de novo cohort will enroll approximately 180 participants). All participants will receive the study intervention abrocitinib oral suspension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •for the Extension Cohort:
- •1. Participants who have completed the treatment phase of the qualifying parent study (age 2 to <12 years old).
- •No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention.
- •Inclusion Criteria for the De Novo Cohort:
- •Children aged 6 to <12 years at the time of informed consent/assent.
- •No contraception methods are required for male participants.
- •Disease Characteristics:
- •Participants who meet all of the following AD criteria:
- •A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and
- •A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
- •Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy.
- •Other Inclusion Criteria:
- •Body weight ≥15 kg
排除标准
- •for the Extension Cohort:
- •Medical Conditions:
- •Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
- •Prior/Concomitant Therapy:
- •Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol.
- •Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment.
- •Diagnostic Assessments:
- •Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria.
- •Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern.
- •Exclusion Criteria for the De Novo Cohort
- •Medical Conditions:
- •Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
- •Have any of the following medical conditions:
- •Infections:
- •Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day
- •History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day
- •Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
- •Infection with HIV, hepatitis B, and/or hepatitis C
- •Evidence of active TB or inadequately treated latent TB.
- •Skin Conditions:
- •- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
- •Other Conditions:
- •Documented history of skeletal dysplasia.
- •Documented history of retinal detachment.
- •History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
- •Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
- •Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
- •Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.
- •Prior/Concomitant Therapy:
- •Prior treatment with a systemic JAK inhibitor for AD.
- •Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.
- •Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study.
- •Prior/Concurrent Clinical Study Experience:
- •Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day
- •Diagnostic Assessments:
- •Hepatic and/or renal and/or hematological abnormalities defined as:
- •AST >2 x ULN
- •Hemoglobin <10 g/dL
- •ALT >2 x ULN
- •ANC <1000/mm3
- •Total bilirubin ≥1.5 x ULN
- •ALC <500/mm3
- •eGFR <60 mL/min/1.73 m2
- •Platelets <150,000 /mm3
- •Other Exclusion Criteria:
- •Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
研究组 & 干预措施
De novo
Experimental
Patients who have not participated other abrocitinib studies
干预措施: Abrocitinib (Drug)
Extension
Experimental
Patients who have completed other abrocitinib studies
干预措施: Abrocitinib (Drug)
结局指标
主要结局
Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
时间窗: 0-24 months
The number of the treatment emergent adverse events, serious adverse events and adverse events leading to discontinuation among patients with moderate-to-severe disease treated with abrocitinib regardless of discontinuation from study treatment.
次要结局
- CFB in Dermatitis Family Impact (DFI) at all scheduled time points(0-24 months)
- Percentage of Participants with Flares(0-24 months)
- CFB in the percentage Body Surface Area (BSA) affected at all scheduled time points(0-24 months)
- Percent Change from Baseline (CFB) in EASI total score at all scheduled time points.(0-24 months)
- Percentage of Responders based on achieving Eczema Area and Severity Index (EASI)-50, EASI-90 and EASI-100 at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib(0-24 months)
- Number of Participants With Clinically Significant Laboratory Abnormalities(0-24 months)
- Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a 2 -point reduction from baseline at all scheduled time points(Baseline, 24 months)
- Percentage of Response based on achieving a ≥4 point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at all scheduled time points in participants aged ≥2 to <6 years(0-24 months)
- Percentage of Response based on achieving a ≥4-point improvement from baseline in the WSI-NRS at all scheduled time points in participants aged ≥6 to 12 years(0-24 months)
- CFB in Children's Dermatology Life Quality Index (CDLQI) at all scheduled time points.(0-24 months)
- CFB in in Infants' Dermatitis Quality of Life (IDQOL) Index at all scheduled time points(0-24 months)
- CFB in Patient-Oriented Eczema Measure (POEM) at all scheduled time points(0-24 months)
- CFB in Patient Global Impression of Severity (PGIS) at all scheduled time points(0-24 months)
- Percentage of Participants Achieving satisfactory response in Tdap/DTaP and/or pneumococcal antibody titers as appropriate in participants who receive Tdap/DTaP and/or pneumococcal vaccinations(0-24 months)
- CFB in Observer Reported Global Impression of Severity (OGIS) at all scheduled time points(0-24 months)
- CFB in the the EuroQol- 5 Dimension Youth (EQ-5D-Y)(0-24 months)
- Number of topical corticosteroid and /or topical calcineurin inhibitor free days(0-24 months)
研究者
研究点 (43)
Loading locations...
相似试验
终止
3 期
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT03559270Eli Lilly and Company374
已完成
3 期
An Extension Study in Participants With Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT01885078Eli Lilly and Company2,877
已完成
2 期
A Long Term, Safety Study of Apricitabine in HIV-infected SubjectsHIV InfectionNCT00367952Avexa42
已完成
3 期
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic DermatitisAtopic DermatitisNCT03334435Eli Lilly and Company1,645
已完成
3 期
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisDermatitis, AtopicNCT03422822Pfizer3,166